Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes.
Nathaniel A CohenJoshua M SteinbergAlexa SilfenCindy TraboulsiTina G RodriguezJorie M SingerShivani PatelRussell D CohenSushila R DalalAtsushi SakurabaJoel PekowDejan MicicDavid T RubinPublished in: Digestive diseases and sciences (2022)
This study demonstrates the effectiveness and long-term safety of tofacitinib in patients with UC. Importantly, we show that the endpoint of endo-histologic healing is achievable with tofacitinib and can occur as early as week 8 of therapy.